Legal
Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.
According to a University College London (UCL) report, British researchers are being shut out of major European research partnerships because of concerns over a no-deal Brexit.
In addition to the states agreeing to pause lawsuits, the FDA accepted Insys’ NDA for an opioid overdose medication.
Four bills aimed at lowering prescription drug prices were advanced out of the U.S. Senate Judiciary Committee this week and will head to a vote on the Senate floor.
Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16.
Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II trial.
Two weeks after filing a lawsuit against his former company from prison, Martin Shkreli has reached a settlement with Retrophin.
Lawsuits against the FDA are fairly common. However, winning the lawsuit will be a tough road for Catalyst, as other pharma companies that challenged the regulatory agency learned.
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act
Novartis was alleged to have held about 80,000 sham events where doctors were wined and dined in order to boost sales of key medications.
PRESS RELEASES